Potemski Piotr, Płuciennik Elzbieta, Bednarek Andrzej K, Kusińska Renata, Pasz-Walczak Grazyna, Jesionek-Kupnicka Dorota, Watala Cezary, Kordek Radzisław
Department of Chemotherapy, Medical University of Łódź, Copernicus Memorial Hospital, Łódź, Poland.
Med Sci Monit. 2006 Dec;12(12):MT57-61. Epub 2006 Nov 23.
The most commonly used methods for detecting HER2 gene amplification in breast cancer are immunohistochemistry and fluorescence in-situ hybridization. The aim of this retrospective study was to assess HER2 expression by real-time RT-PCR.
MATERIAL/METHODS: Expression of HER2 was analyzed by real-time RT-PCR and immunohistochemistry in specimens of invasive ductal breast cancer tissue obtained from 131 women during radical mastectomy.
There was a highly significant difference in mean relative gene expression between HER2-positive and HER2-negative patients as assessed by immunostaining (22.10+/-41.89 vs. 3.17+/-8.76; p<0.001). With a median follow-up of 56 months, the cancer-specific survival of HER2-positive patients assessed by RT-PCR was worse in all cases and in the node-positive group. In multivariate analysis, HER2 status was an independent prognostic factor in all patients.
Real-time RT-PCR is a valuable method for determining HER2 status, but the selection of the cut-off point of the relative gene expression differentiating between HER2-negative and -positive tumors is essential.
检测乳腺癌中HER2基因扩增最常用的方法是免疫组织化学和荧光原位杂交。这项回顾性研究的目的是通过实时逆转录聚合酶链反应评估HER2表达。
材料/方法：对131名接受根治性乳房切除术的女性患者的浸润性导管癌组织标本进行实时逆转录聚合酶链反应和免疫组织化学分析，以检测HER2的表达。
通过免疫染色评估，HER2阳性和HER2阴性患者之间的平均相对基因表达存在高度显著差异（22.10±41.89对3.17±8.76；p<0.001）。中位随访56个月，通过逆转录聚合酶链反应评估，HER2阳性患者在所有病例和淋巴结阳性组中的癌症特异性生存率均较差。在多变量分析中，HER2状态是所有患者的独立预后因素。
实时逆转录聚合酶链反应是确定HER2状态的一种有价值的方法，但区分HER2阴性和阳性肿瘤的相对基因表达临界值的选择至关重要。
Zotero 插件